{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:31:31Z","timestamp":1777530691483,"version":"3.51.4"},"reference-count":29,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Cardiovasc Pharmacol Ther"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:p>Results of the carefully executed Evaluation of Treatment with Angiotensin Converting Enzyme Inhibitors and the Risk of Lung Cancer (ERACER) study, reported in this issue, echo those of several previous observational analyses of the association of long-term angiotensin-converting enzyme (ACE) inhibitor use with incident lung cancer. These epidemiological drug-safety analyses merit cautious interpretation. First, the number needed to harm (NNH) of 6667 reported in ERACER for ACE inhibitors compared with angiotensin-2 receptor blockers (ARBs) after approximately 12 years of follow-up should be balanced against therapeutic benefits. Previously reported meta-analyses of randomized controlled trials (RCTs) over a mean 4.3-year follow-up suggested number needed to treat (NNT) of 67 for all-cause mortality, 116 for cardiovascular mortality, and 86 for a composite of myocardial infarction (MI) and stroke for ACE inhibitors, compared with nonsignificant benefits for ARBs on the mortality outcomes and NNT of 157 for ARBs on the MI\/stroke composite. Second, confounding by indication is possible because until 2013, ACE inhibitors, not ARBs, were first-line medications for heart failure, which is associated with incident lung cancer. Third, findings may be compromised by detection bias due to investigation of ACE inhibitor-induced cough, or by residual confounding due to influential factors not measurable in the available data, such as socioeconomic status (SES) or smoking history. The important questions raised by ERACER and similar drug-safety analyses should be addressed in long-term RCTs or in enhanced large-database pharmacoepidemiological analyses, measuring both NNH and NNT and controlling for SES, indication, medication, and dosage.<\/jats:p>","DOI":"10.1177\/10742484211000521","type":"journal-article","created":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T02:06:17Z","timestamp":1616724377000},"page":"371-374","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Modest Association of Long-Term ACE Inhibitor Treatment With Lung Cancer: The Promise and Pitfalls of Epidemiological Drug-Safety Analyses"],"prefix":"10.1177","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8704-7271","authenticated-orcid":false,"given":"Kathleen A.","family":"Fairman","sequence":"first","affiliation":[{"name":"Midwestern University College of Pharmacy, Glendale Campus (CPG), Glendale, AZ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,3,25]]},"reference":[{"key":"bibr1-10742484211000521","doi-asserted-by":"publisher","DOI":"10.1177\/1074248420987054"},{"key":"bibr2-10742484211000521","unstructured":"European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. ENCePP guide on methodological standards in pharmacoepidemiology. 5.2. Bias (systematic error). January 15, 2021. Updated March 15, 2021. Accessed March 18, 2021. http:\/\/www.encepp.eu\/standards_and_guidances\/methodologicalGuide5_2.shtml"},{"key":"bibr3-10742484211000521","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4209"},{"key":"bibr4-10742484211000521","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030747"},{"key":"bibr5-10742484211000521","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.120.006687"},{"issue":"3","key":"bibr6-10742484211000521","first-page":"124","volume":"11","author":"Golias C","year":"2007","journal-title":"Hippokratia"},{"issue":"7","key":"bibr7-10742484211000521","first-page":"881","volume":"29","author":"Cove\u00f1as R","year":"2014","journal-title":"Histol Histopathol"},{"key":"bibr8-10742484211000521","unstructured":"EurekAlert! Certain blood pressure drugs linked to increased risk of lung cancer. October 24, 2018. Accessed March 18, 2021. https:\/\/www.eurekalert.org\/pub_releases\/2018-10\/b-cbp102318.php"},{"key":"bibr9-10742484211000521","unstructured":"Bassett M. Group of blood pressure drugs linked to lung cancer\u201414% higher likelihood in users of ACE inhibitors; causal relationship unproven. MedPage Today. October 25, 2018. Accessed March 18, 2021. https:\/\/www.medpagetoday.com\/hematologyoncology\/lungcancer\/75927"},{"key":"bibr10-10742484211000521","unstructured":"Glatter R. Common blood pressure medication linked to increased risk of lung cancer. Forbes. October 27, 2018. Accessed March 18, 2021. https:\/\/www.forbes.com\/sites\/robertglatter\/2018\/10\/27\/common-blood-pressure-medication-linked-to-increased-risk-of-lung-cancer\/?sh=25a6cc677b4e"},{"key":"bibr11-10742484211000521","doi-asserted-by":"crossref","unstructured":"Bonner L. Study links ACEIs and lung cancer, but it shouldn\u2019t raise alarm bells. PharmacyToday. 2019;25(1):P7. Updated January 1, 2019. Accessed March 18, 2021. https:\/\/www.pharmacytoday.org\/article\/S1042-0991(18)31844-9\/fulltext","DOI":"10.1016\/j.ptdy.2018.12.027"},{"key":"bibr12-10742484211000521","unstructured":"Ireland N. New study associates highly effective blood pressure medication with small risk of cancer. CBC. October 30, 2018. Accessed March 18, 2021. https:\/\/www.cbc.ca\/news\/health\/blood-pressure-medication-ace-inhibitors-cancer-risk-1.4882562"},{"key":"bibr13-10742484211000521","unstructured":"U.S. Pharmacist. Use of ACEIs to lower blood pressure linked to higher lung-cancer risk. November 7, 2018. Accessed March 18, 2021. https:\/\/www.uspharmacist.com\/article\/use-of-aceis-to-lower-blood-pressure-linked-to-higher-lungcancer-risk"},{"key":"bibr14-10742484211000521","unstructured":"Reinberg S. Lung cancer risk tied to common blood pressure drug. HealthDay. October 24, 2018. Accessed March 18, 2021. https:\/\/consumer.healthday.com\/cancer-information-5\/lung-cancer-news-100\/lung-cancer-risk-tied-to-common-blood-pressure-drug-738929.html#:\u223c:text=For%20those%20who%20took%20them,any%20risk%20for%20lung%20cancer"},{"key":"bibr15-10742484211000521","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4337"},{"key":"bibr16-10742484211000521","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2014.11.179"},{"key":"bibr17-10742484211000521","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2009.03.001"},{"key":"bibr18-10742484211000521","doi-asserted-by":"publisher","DOI":"10.7326\/M16-2607"},{"key":"bibr19-10742484211000521","doi-asserted-by":"publisher","DOI":"10.7326\/M18-2159"},{"key":"bibr20-10742484211000521","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0192999"},{"issue":"9","key":"bibr21-10742484211000521","first-page":"671","volume":"16","author":"Gian B","year":"2010","journal-title":"J Manag Care Pharm"},{"key":"bibr22-10742484211000521","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.033603"},{"key":"bibr23-10742484211000521","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-020-06950-w"},{"key":"bibr24-10742484211000521","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09895-1"},{"key":"bibr25-10742484211000521","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e31829e8807"},{"key":"bibr26-10742484211000521","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.03.004"},{"key":"bibr27-10742484211000521","doi-asserted-by":"publisher","DOI":"10.1177\/1074248420984082"},{"key":"bibr28-10742484211000521","unstructured":"Rapid response letters to\n                      BMJ\n                      . Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study. October 25, 2018. Updated February 28, 2019. Accessed March 15, 2021. https:\/\/www.bmj.com\/content\/363\/bmj.k4209\/rapid-responses"},{"key":"bibr29-10742484211000521","unstructured":"American Heart Association. More than 100 million Americans have high blood pressure, AHA says. July 31, 2018. Accessed March 18, 2021. https:\/\/www.heart.org\/en\/news\/2018\/05\/01\/more-than-100-million-americans-have-high-blood-pressure-aha-says"}],"container-title":["Journal of Cardiovascular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10742484211000521","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10742484211000521","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10742484211000521","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:43:23Z","timestamp":1777394603000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10742484211000521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,25]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1177\/10742484211000521"],"URL":"https:\/\/doi.org\/10.1177\/10742484211000521","relation":{},"ISSN":["1074-2484","1940-4034"],"issn-type":[{"value":"1074-2484","type":"print"},{"value":"1940-4034","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,25]]}}}